# Phase 2 Triple Negative Breast Neoplasms trials: 148 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 148 trials in phase 2 for Triple Negative Breast Neoplasms that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Triple Negative Breast Neoplasms trials: 148 rows for $7.40, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/triple-negative-breast-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 148
- Recruiting or not yet: 148
- Read on: November 19, 2026

## Trials

The 25 newest of 148, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 3, 2026 | NCT07914309 | Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer | Washington University School of Medicine | Phase 2 | Not yet recruiting | Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC), Breast Cancer | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914309) |
| October 20, 2026 | NCT07884201 | Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment | Fudan University | Phase 2 | Not yet recruiting | Breast Cancer, TNBC - Triple-Negative Breast Cancer, Immunotherapy | 572 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884201) |
| October 15, 2026 | NCT07876557 | A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative... | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 | Recruiting | Triple-negative Breast Cancer | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876557) |
| October 7, 2026 | NCT07862751 | US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving... | Emory University | Phase 2 | Not yet recruiting | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862751) |
| October 5, 2026 | NCT07857486 | Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer | Institut Paoli-Calmettes | Phase 2 | Not yet recruiting | Early Triple-Negative Breast Cancer | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857486) |
| August 26, 2026 | NCT07788222 | Sacituzumab Govitecan and Q901 in Advanced TNBC | Yonsei University | Phase 2 | Not yet recruiting | Triple Negative Breast Neoplasms | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788222) |
| August 26, 2026 | NCT07786428 | Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC | University of Texas Southwestern Medical Center | Phase 2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07786428) |
| August 17, 2026 | NCT07768436 | A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Adenocarcinoma of the Breast, Breast Cancer, Triple Negative Breast Cancer | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768436) |
| August 7, 2026 | NCT07752550 | Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer | Harbin Medical University | Phase 2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752550) |
| August 4, 2026 | NCT07743632 | Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC | University of Kansas Medical Center | Phase 2 | Not yet recruiting | Breast Cancer, Triple Negative Breast Cancer | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743632) |
| August 3, 2026 | NCT07743190 | A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative... | Medical University of South Carolina | Phase 2 | Recruiting | Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743190) |
| July 23, 2026 | NCT07721259 | A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden | University of Washington | Phase 2 | Not yet recruiting | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721259) |
| June 10, 2026 | NCT07638852 | Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM. | Fudan University | Phase 2 | Recruiting | TNBC, Triple Negative Breast Cancer, Brain Metastasases | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638852) |
| June 3, 2026 | NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or... | GV20 Therapeutics | Phase 2 | Not yet recruiting | Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and... | 227 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623642) |
| May 28, 2026 | NCT07610525 | Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy, Phase 2 | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610525) |
| May 22, 2026 | NCT07601178 | QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With... | Jiangsu Cancer Institute & Hospital | Phase 2 | Recruiting | TNBC, Triple Negative Breast Cancer | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601178) |
| April 27, 2026 | NCT07552181 | Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | TNBC - Triple-Negative Breast Cancer, TNBC, Early Stage Triple-Negative Breast Carcinoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552181) |
| April 14, 2026 | NCT07528768 | HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. | The University of The West Indies | Phase 2 | Not yet recruiting | Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07528768) |
| April 3, 2026 | NCT07509515 | QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. | Fudan University | Phase 2 | Not yet recruiting | Triple-negative Breast Cancer (TNBC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509515) |
| March 23, 2026 | NCT07487519 | Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or... | Shanghai Henlius Biotech | Phase 2 | Not yet recruiting | Breast Cancer (Triple Negative Breast Cancer (TNBC)) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07487519) |
| March 12, 2026 | NCT07466303 | Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer | Xijing Hospital | Phase 2 | Not yet recruiting | Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07466303) |
| March 9, 2026 | NCT07458204 | Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer | Institut Jean-Godinot | Phase 2 | Not yet recruiting | Triple-negative Breast Cancer | 760 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458204) |
| March 9, 2026 | NCT07458113 | Sac-TMT for Active TNBC Brain Metastases | Yale University | Phase 2 | Not yet recruiting | Metastatic Triple Negative Breast Cancers | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458113) |
| March 9, 2026 | NCT07457359 | Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Recruiting | TNBC, Triple Negative Breast Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07457359) |
| March 2, 2026 | NCT07441512 | A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | TNBC - Triple-Negative Breast Cancer, TNBC | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441512) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 17 |
| Tianjin Medical University Cancer Institute and Hospital | 5 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 4 |
| Memorial Sloan Kettering Cancer Center | 4 |
| Emory University | 3 |
| Sun Yat-sen University | 3 |
| UNC Lineberger Comprehensive Cancer Center | 3 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 3 |
| Henan Cancer Hospital | 3 |
| UNICANCER | 3 |
| First Affiliated Hospital of Zhejiang University | 2 |
| University of Washington | 2 |
| Dana-Farber Cancer Institute | 2 |
| M.D. Anderson Cancer Center | 2 |
| Hebei Medical University Fourth Hospital | 2 |
| Medical University of South Carolina | 2 |
| Roswell Park Cancer Institute | 2 |
| Shengjing Hospital | 2 |
| Shanghai Junshi Bioscience Co., Ltd. | 2 |
| Xijing Hospital | 2 |
| Universitaire Ziekenhuizen KU Leuven | 2 |
| H. Lee Moffitt Cancer Center and Research Institute | 2 |
| Tel-Aviv Sourasky Medical Center | 1 |
| Providence Health & Services | 1 |
| Yonsei University | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 56 |
| United States | 45 |
| France | 5 |
| Canada | 4 |
| Belgium | 3 |
| Nigeria | 2 |
| United Kingdom | 2 |
| Japan | 2 |
| Italy | 2 |
| Israel | 1 |
| Barbados | 1 |
| Ghana | 1 |
| Jamaica | 1 |
| Taiwan | 1 |
| India | 1 |
| Poland | 1 |
| Spain | 1 |
| Portugal | 1 |
| Belarus | 1 |
| Russia | 1 |
| Netherlands | 1 |
| Switzerland | 1 |
| Indonesia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Electricians in the United States](https://specstream.ai/data/businesses/electricians/united-states)
- [Israeli restaurants in the United States](https://specstream.ai/data/businesses/israeli-restaurants/united-states)
- [Pool cleaning companies in the United States](https://specstream.ai/data/businesses/pool-cleaning-companies/united-states)
- [Ukrainian restaurants in the United States](https://specstream.ai/data/businesses/ukrainian-restaurants/united-states)
- [Boat and ship manufacturers in the United States](https://specstream.ai/data/businesses/boat-and-ship-manufacturers/united-states)
- [Equipment rental companies in the United States](https://specstream.ai/data/businesses/equipment-rental-companies/united-states)
